Episode: 46 - Leveraging Albumin and IgG FcRn-Mediated Regulation in Therapeutic Development

The Chain: Protein Engineering Podcast

Innhold levert av Cambridge Healthtech Institute. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Cambridge Healthtech Institute eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

1+ y ago 36:20

MP3•Episoder hjem

Jan Terje Andersen, professor of biomedical innovation in the Department of Pharmacology at the University of Oslo and research group leader in the Department of Immunology at the Oslo University Hospital, has spent nearly two decades studying neonatal Fc receptors (FcRns) and their interactions with prominent blood proteins albumin and IgG. He sits down with moderator Nimish Gera, vice president of biologics at Mythic Therapeutics, to discuss the unique properties of FcRn and how it can be leveraged for novel therapeutic development. Additionally, Andersen details the mechanics of FcRn binding, why it prolongs albumin and IgG half-lives, and notable FcRn technological advancements and research findings in animal and human models. He also talks about engineering blood proteins for optimal function and launching his new venture, Authera, the preclinical stage biotech company using an FcRn-centered platform to study the receptor’s versatility across multiple cell types.
Links from this episode:
University of Oslo
Mythic Therapeutics
Authera

65 episoder

#Science #Biology #Cambridge Healthtech Institute #Proteins #Protein Engineering #Scientists #RD In #Antibodies #Bispecific Antibodies #Solid Tumors